Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Guided Therapeutics (GTHP) over the last 13 years, with Q3 2025 value amounting to -$257000.0.

  • Guided Therapeutics' Other Non Operating Income fell 17634.41% to -$257000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $114000.0, marking a year-over-year increase of 20363.64%. This contributed to the annual value of $18000.0 for FY2024, which is 5384.62% down from last year.
  • As of Q3 2025, Guided Therapeutics' Other Non Operating Income stood at -$257000.0, which was down 17634.41% from $64000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Other Non Operating Income ranged from a high of $763000.0 in Q3 2021 and a low of -$473000.0 during Q2 2021
  • Over the past 5 years, Guided Therapeutics' median Other Non Operating Income value was $6500.0 (recorded in 2022), while the average stood at $33111.1.
  • In the last 5 years, Guided Therapeutics' Other Non Operating Income plummeted by 64705.88% in 2024 and then soared by 970000.0% in 2025.
  • Over the past 5 years, Guided Therapeutics' Other Non Operating Income (Quarter) stood at -$130000.0 in 2021, then skyrocketed by 108.46% to $11000.0 in 2022, then plummeted by 372.73% to -$30000.0 in 2023, then surged by 796.67% to $209000.0 in 2024, then tumbled by 222.97% to -$257000.0 in 2025.
  • Its last three reported values are -$257000.0 in Q3 2025, $64000.0 for Q2 2025, and $98000.0 during Q1 2025.